RIPK1 and breast carcinoma: Conversely, Bufalin has been found to induce RIP1-dependent and ROS-dependent programmed necrosis in MDA-MB-468 and T47D cells in breast cancer by targeting the RIP1/RIP3/PGAM5 pathway [81].